Suchergebnisse - "Gulick, Roy M"

PubPharm (52)

1

Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women : HPTN 069/ACTG A5305

enthalten in: The Journal of antimicrobial chemotherapy | 2022

von Brown, T. | Yuhas, K. | Mayer, K. | +9

2

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

enthalten in: The New England journal of medicine | 2021

von Landovitz, R. | Donnell, D. | Clement, M. | +107

CommentIn: N Engl J Med. 2021 Aug 12;385(7):652-653. - PMID 34379927

3

Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2021

von Ellsworth, G. | Burke, L. | Wells, M. | +10

4

ART in HIV-Positive Persons With Low Pretreatment Viremia : Results From the START Trial

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2019

von Sereti, I. | Gulick, R. | Krishnan, S. | +7

5

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

enthalten in: Nature medicine | 2018

von Bar-On, Y. | Gruell, H. | Schoofs, T. | +30

CommentIn: Nature. 2018 Sep;561(7724):468-470. - PMID 30258147

6

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events

enthalten in: Pharmacogenetics and genomics | 2018

von Haas, D. | Bradford, Y. | Verma, A. | +9

7

No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP) : Findings from HPTN 069/ACTG A5305

enthalten in: PloS one | 2018

von Kapadia, S. | Wu, C. | Mayer, K. | +9

8

Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women : A Phase 2 Randomized Trial

enthalten in: Annals of internal medicine | 2017

von Gulick, R. | Wilkin, T. | Chen, Y. | +27

9

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants

enthalten in: The Journal of infectious diseases | 2017

von Mollan, K. | Tierney, C. | Hellwege, J. | +13

10

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)

enthalten in: The Journal of infectious diseases | 2017

von Gulick, R. | Wilkin, T. | Chen, Y. | +26

1
2
3
4
5
6
Nächster »
[6]